Fuda Cancer Hospital
Gallbladder cancer treatment cost in China is influenced by the disease stage and selected therapy, with proton-beam therapy ranging from $36,500 to $47,500. Surgical resection and chemotherapy are primary options, while advanced proton-beam therapy runs from $36,500 to $47,500. Total expenses depend on hospital tier and the complexity of the multidisciplinary approach. Patients can achieve 40–70% savings compared to the US. Top destinations include Guangzhou, Shanghai, and Xiamen.
Typical Gallbladder Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients find significant value in China’s specialized minimally invasive oncology centers. Fuda Cancer Hospital in Guangzhou is a Joint Commission International (JCI) accredited facility. It offers alternatives to traditional chemotherapy like NanoKnife and cryosurgery. Dr. Liu Shi Xin at Xiamen Humanity Hospital provides precision radiotherapy for abdominal cancers. These experts focus on complex cases that require advanced precision techniques.
| China | Turkey | Austria | |
| Proton-beam therapy | from $36,500 | from $1,500 | from $80,000 |
| Proton therapy for prostate cancer | from $42,500 | from $30,000 | from $80,000 |
| Proton therapy for breast cancer | from $38,500 | from $30,000 | from $55,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Brachytherapy | from $7,200 | from $4,000 | from $15,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Gallbladder cancer treatment in China is successful when surgery achieves a total tumor removal. Specialist centers use radical cholecystectomy and liver resection. Advanced clinics also offer cryosurgery and NanoKnife for late-stage cases. JCI-accredited facilities in Guangzhou provide multidisciplinary care for international patients.
Bookimed Expert Insight: Fuda Cancer Hospital has treated over 30,000 international patients using unique minimally invasive protocols. They often apply over 10 different non-surgical therapies for late-stage cases. This specific focus on advanced stages makes it a distinct choice for patients who are ineligible for traditional surgery.
Patient Consensus: Patients note that success depends largely on finding a surgeon with deep experience in biliary procedures. They also emphasize planning for long-term follow-up care as recurrence risk remains a major concern even after successful surgery.
Advanced gallbladder cancer treatments in China focus on precision local destruction and robotic surgery. Specialized centers utilize NanoKnife, cryosurgery, and vascular interventional therapy to treat complex tumors. These minimally invasive options aim to preserve healthy tissue and improve recovery times in high-volume oncology hospitals.
Bookimed Expert Insight: Patient volume is a major quality signal in China. Fuda Cancer Hospital has treated over 30,000 international patients. Large-scale centers often provide specialized techniques like NanoKnife and vascular intervention that are less common elsewhere. Leading specialists like Dr. Leng Yin bring international experience from top hospitals in Thailand. These high-volume facilities often manage advanced cases that other institutions might consider unresectable.
Patient Consensus: Patients emphasize finding a specialized hepatobiliary team rather than a general surgeon. Managing jaundice through biliary stenting is often the first priority to make further treatment possible.
The leading hospitals in China for gallbladder cancer include the Fuda Cancer Hospital in Guangzhou and the Fudan University Shanghai Cancer Center. These centers utilize multidisciplinary teams and advanced technologies like NanoKnife to treat complex cases. Many facilities hold JCI accreditation, ensuring high-quality surgical and oncological care for international patients.
Bookimed Expert Insight: Data from Fuda Cancer Hospital shows they treat over 30,000 patients from 100 countries. This high volume of international cases suggests the hospital has refined its logistics for non-residents. Their focus on minimally invasive therapies like vascular interventional therapy provides an alternative when traditional surgery is not possible.
Patient Consensus: Patients often emphasize that finding a surgeon who performs a high volume of gallbladder procedures is vital. They note that traveling to major city centers is necessary to access experienced teams and accurate pathology reviews.
Chinese doctors typically disclose a cancer diagnosis to family members before informing the patient. This cultural practice prioritizes family consensus over individual autonomy. Relatives often decide how much information the patient receives to protect them from emotional distress and maintain hope during treatment.
Bookimed Expert Insight: JCI-accredited facilities like Fuda Cancer Hospital in Guangzhou frequently manage international patients from over 100 countries. These institutions often bridge cultural gaps by offering more direct communication styles than traditional public hospitals. If you prefer full disclosure, specify this during your first meeting with oncologists like Dr. Leng Yin.
Patient Consensus: Patients note that families often request doctors avoid the word cancer entirely. Many recommend bringing a bilingual advocate to ensure the doctor respects the patient's personal preference for direct truth.
Travelers seeking medical care in China primarily require an S-series visa for private affairs. Short-term treatment under 180 days uses the S2 visa. Chronic conditions requiring longer stays or residence permits necessitate the S1 visa. Both require official hospital invitations and certified medical records.
Bookimed Expert Insight: Documentation needs vary significantly based on the intended procedure. For example, specialists like Dr. Leng Yin at Fuda Cancer Hospital treat over 30,000 international patients. This high volume means their administrative teams are familiar with S2 visa invitation requirements. Getting a detailed treatment timeline helps avoid the need for unexpected visa extensions during recovery.
Patient Consensus: Patients warn that standard tourist visas rarely suffice for complex cancer care. They emphasize securing a detailed hospital letter to avoid extra scrutiny at the embassy.
Traditional Chinese Medicine (TCM) is frequently used in China as a supportive therapy alongside standard gallbladder cancer protocols. It never replaces surgery or chemotherapy. Instead, it functions as a complementary tool to manage side effects, improve appetite, and support physical recovery during systemic treatment.
Bookimed Expert Insight: Patients seeking integrative care in China should focus on centers with JCI accreditation like Fuda Cancer Hospital in Guangzhou. While TCM is common, these top-tier facilities prioritize minimally invasive technologies like NanoKnife and cryosurgery for advanced cases. The most effective approach seen in our data is utilizing TCM strictly for rehabilitation after high-tech surgical interventions, rather than as a primary tumor-fighting method.
Patient Consensus: Patients note that TCM helps them tolerate the harshness of chemotherapy by improving sleep and digestion. Many emphasize the importance of disclosure, as some herbs can unexpectedly affect liver enzymes or blood clotting during recovery.